Clinical Trial Update: Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes [Phase 1]

View source ↗

Summary

This Phase 1 study reports pharmacokinetics, safety and tolerability of single doses of Opicinumab (BIIB033) produced by two manufacturing processes; the trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Optic Neuritis

Drugs mentioned

• Opicinumab (BIIB033) (opicinumab)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis, Acute Optic Neuritis | Phase 1 | Status: COMPLETED